Volume 36 · Number 1
JANUARY 2006
Challenges in Differentiating and Diagnosing Psychotic Depression
By Anthony J. Rothschild, MD; Benoit H. Mulsant, MD; Barnett S. Meyers, MD; Alastair J. Flint, MD, FRCPC, FRANZCP
Major depression with psychotic features (MD-Psy), a disorder with considerable morbidity and mortality, is more common than is generally realized and is encountered frequently in clinical practice. Although studies conducted in both inpatient and outpatient settings have estimated that 16% to 54% of adults with depression are also psychotic, MD-Psy often is not diagnosed accurately because the psychosis may be subtle, intermittent, or concealed leading to a misdiagnosis of nonpsychotic depression.
ABOUT THE AUTHORS
Dr. Rothschild is Irving S. and Betty Brudnick Professor of Psychiatry, Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA. Dr. Mulsant is professor of psychiatry, Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA; clinical director, Geriatric Mental Health Program, Centre for Addiction and Mental Health, Toronto, and professor, Department of Psychiatry, University of Toronto. Dr. Meyers is professor of psychiatry, Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, Westchester, NY. Dr. Flint is professor, Department of Psychiatry, University of Toronto, and head, Geriatric Psychiatry Program, University Health Network, Toronto, Ontario, Canada; the Geriatric Program and Research Institute, Toronto Rehabilitation Institute, Toronto; and the Toronto General Research Institute, Toronto.
Address reprint requests to: Anthony J. Rothschild, MD, University of Massachusetts Medical School, 361 Plantation Street, Worcester, MA 01605; or e-mail rothscha@ummhc.org.
Dr. Rothschild disclosed relevant financial relationships with Lilly and Pfizer. Dr. Mulsant disclosed relevant financial relationships with Pfizer, Eli Lilly, Forest/Lundbeck, AstraZeneca, Janssen, and Alkermes. Dr. Flint disclosed a relevant financial relationship with Pfizer Canada. Dr. Meyers disclosed no relevant financial relationships.
This research was supported in part by National Institutes of Mental Health grants MH 62518, MH 62446, MH 62565, and MH 62624 and the Irving S. and Betty Brudnick Endowed Chair in Psychiatry, University of Massachusetts Medical School.
What Do We Know and What Don’t We Know?
Jan Fawcett, MD
Psychotic Depression
Barnett S. Meyers, MD
A 38-year-old Man With Anxiety, Intrusive Violent Thoughts
Pharmacotherapy of Major Depression with Psychotic Features: What is the Evidence?
Carmen Andreescu, MD;
Benoit H. Mulsant, MD;
Anthony J. Rothschild, MD;
Alastair J. Flint, MD, FRCPC, FRANZCP;
Barnett S. Meyers, MD;
Ellen Whyte, MD
Research Assessment of Patients With Psychotic Depression: The STOP-PD Approach
Alastair J. Flint, MD, FRCPC, FRANZCP;
Ayal Schaffer, MD, FRCPC;
Barnett S. Meyers, MD;
Anthony J. Rothschild, MD;
Benoit H. Mulsant, MD
Methodological Issues in Designing a Randomized Controlled Trial for Psychotic Depression: The STOP-PD Study
Barnett S. Meyers, MD;
Catherine Peasley-Miklus, PhD;
Alastair J. Flint, MD, FRCPC, FRANZCP;
Benoit H. Mulsant, MD;
Anthony J. Rothschild, MD
The Clinical Significance of Psychotic Depression
Diana Feldman, MD
